A tool to help lung cancer patients make treatment decisions
Improving Decision-Making Encounters in Lung Cancer (I DECide) II: A Randomized Control Trial Of A Low-Literacy Conversation Tool
NA · OHSU Knight Cancer Institute · NCT05407168
This study tests a new conversation tool to help lung cancer patients make better treatment decisions compared to standard care.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | OHSU Knight Cancer Institute (other) |
| Locations | 4 sites (Hillsboro, Oregon and 3 other locations) |
| Trial ID | NCT05407168 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a conversation tool designed to improve patient-centered health and decision-making outcomes for individuals with lung cancer. The study involves a randomized controlled trial where participants are divided into two groups: one receiving a decision aid and the other receiving standard care. Additionally, qualitative interviews will be conducted to gather insights on the decision-making process. The aim is to enhance understanding of the information patients need to make informed treatment choices, particularly focusing on those with lower health literacy.
Who should consider this trial
Good fit: Ideal candidates include patients with suspected lung cancer who are fluent in English and have a life expectancy of more than six months.
Not a fit: Patients who do not have lung cancer or those with severe cognitive impairments may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could empower lung cancer patients to make more informed treatment decisions, leading to better health outcomes.
How similar studies have performed: Other studies have shown promise in using decision aids for patient engagement in treatment choices, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * AIM 1: Suspected lung cancer * AIM 1: English fluency * AIM 1: \> 6-month life expectancy * AIM 1: Score of ≥ 3 on the cognitive impairment screener * AIM 2 PARTICIPANTS: Participation in Aim 1 * AIM 2 CLINICIANS: Discussing lung cancer treatment decisions with Aim 1 participants
Where this trial is running
Hillsboro, Oregon and 3 other locations
- Hillsboro Medical Center — Hillsboro, Oregon, United States (RECRUITING)
- Adventist Health Portland — Portland, Oregon, United States (RECRUITING)
- OHSU Knight Cancer Institute — Portland, Oregon, United States (RECRUITING)
- Portland VA Medical Center — Portland, Oregon, United States (RECRUITING)
Study contacts
- Principal investigator: Donald R Sullivan, MD, MA, MCR — OHSU Knight Cancer Institute
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Carcinoma